FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1530-1531 October 6, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Post-marketing surveillance has revealed a higher incidence of reactivation of granulomatous infections — most notably, tuberculosis¹ and histoplasmosis² — in patients receiving the tumor necrosis factor (TNF-) inhibitor infliximab (Remicade, Centocor). Other opportunistic infections have been reported as well. Here we describe a patient receiving infliximab who had reactivation of cerebral toxoplasmosis.

The patient was a 36-year-old woman in whom rheumatoid arthritis was diagnosed in 2000. She was treated with prednisone at a dose of 10 mg per day, weekly methotrexate, and a high-dose nonsteroidal antiinflammatory drug for the first year. In early 2001, leflunomide (Arava, . . . [Full Text of this Article]

This article has been cited by other articles:

• D'Haens, G. (2007). Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 [Full Text]